Report Highlights

The United States' Role in the Global Anti-Counterfeit Packaging Supply Chain

The United States occupies a dual position in the global anti-counterfeit packaging supply chain — it is simultaneously the world's largest demand center and a major technology innovator. Domestically, the U.S. imports a substantial share of raw authentication inputs, including specialty inks, holographic substrates, and RFID inlays, primarily from suppliers in Germany, Japan, South Korea, and China. Companies such as Avery Dennison source RFID inlay components from Asia-Pacific manufacturing hubs, while CCL Industries processes authentication films at North American converting facilities. The U.S. market consumed an estimated 4.2 billion authentication labels and devices in 2024, reinforcing its centrality in global demand flows.

On the export and technology side, U.S. firms export authentication software platforms, track-and-trace middleware, and serialization solutions globally, particularly to the European Union and Latin American pharmaceutical markets. Authentix and Zebra Technologies, both U.S.-headquartered, supply verification infrastructure to governments and regulated industries across more than 40 countries. The U.S. also sets global standards through FDA and GS1 US frameworks that downstream supply chain actors worldwide are compelled to adopt, giving American technology providers an embedded first-mover advantage in standard-setting that translates directly into export revenue and licensing income.

Growth Drivers for U.S. Anti-Counterfeit Packaging Trade and Production

Three structural forces are driving expansion in U.S. anti-counterfeit packaging production and trade. First, regulatory escalation is the most immediate accelerant. Full DSCSA enforcement, combined with the FDA's ongoing push for serialized traceability across medical devices under UDI regulations, has created a compliance-driven procurement cycle across pharmaceutical and medtech supply chains. Hospitals, distributors, and third-party logistics providers are mandated buyers, creating durable, non-cyclical demand for serialization hardware and software that U.S. vendors are well-positioned to supply domestically and internationally.

Second, e-commerce channel expansion is intensifying the need for consumer-facing authentication at the package level. U.S. online retail surpassed USD 1.1 trillion in 2023, and counterfeit goods entering through third-party marketplace platforms — a documented problem for Amazon's marketplace — have accelerated brand owner investment in QR-code-linked authentication and near-field communication tags on individual product units. Third, reshoring of pharmaceutical and electronics manufacturing under the CHIPS Act and Inflation Reduction Act is expanding domestic production nodes where anti-counterfeit packaging must be embedded at the point of manufacture, creating new greenfield demand within U.S. borders rather than at import entry points.

Supply Chain Risks and Trade Barriers

The most critical supply chain risk for U.S. anti-counterfeit packaging is raw material import dependency. Specialty security inks, holographic origination films, and RFID chip components are predominantly sourced from Asia-Pacific and European suppliers. Any disruption to Japanese polyester film exports, South Korean chip fabrication, or Chinese rare-earth-based ink pigments would create immediate production bottlenecks for U.S. authentication label converters. The 2021–2022 semiconductor shortage demonstrated this vulnerability directly — RFID inlay lead times extended to 52 weeks at peak disruption, forcing several U.S. packaging brands to delay product launches and accept inferior authentication solutions as interim substitutes.

Trade policy risk compounds this dependency. Section 301 tariffs on Chinese goods include components used in authentication packaging manufacturing, adding 7.5%–25% cost burdens on RFID chips, specialty substrates, and certain printing consumables sourced from China. While U.S. brands have partially diversified toward Taiwanese and Vietnamese suppliers, the transition is incomplete and price-sensitive. Additionally, intellectual property enforcement asymmetry poses a structural export barrier — U.S. anti-counterfeit technology firms operating in emerging markets face local regulatory barriers, mandatory technology transfer demands, and state-sponsored IP replication that reduces the competitive life of proprietary authentication technologies to three to four years before local alternatives emerge.

Trade and Investment Opportunities in the United States

The most immediate investment opportunity lies in domestic RFID inlay manufacturing. Currently, the U.S. has no large-scale domestic RFID inlay fabrication capability — virtually all inlays are imported and converted domestically. An onshore inlay fabrication facility, positioned near existing converting clusters in Ohio or North Carolina, would capture margin currently flowing to Asian suppliers while qualifying for domestic content preferences under federal procurement and healthcare reimbursement frameworks. A manufacturing investment of USD 80–120 million in this node would generate compelling returns given the compounding retailer mandate pipeline driving demand through 2030.

Export opportunity is equally significant. Latin American pharmaceutical markets — Mexico, Brazil, and Colombia — are implementing serialization mandates modeled closely on U.S. DSCSA architecture. U.S. track-and-trace software vendors and systems integrators are uniquely positioned to capture early-mover advantage in these markets given regulatory familiarity and existing commercial relationships with multinational pharmaceutical clients operating across both jurisdictions. Strategic partnership with regional Mexican packaging converters, specifically targeting the Monterrey industrial corridor, offers a low-capital route to production-level market entry before European and Chinese competitors consolidate their positions in Latin American healthcare packaging.

Market at a Glance

Leading Market Participants

• Avery Dennison Corporation
• CCL Industries Inc.
• 3M Company
• Zebra Technologies Corporation
• Authentix Inc.
• Impinj Inc.
• Digimarc Corporation
• AlpVision SA
• INX International Ink Co.
• Systech International

Regulatory and Trade Policy Environment

The U.S. regulatory framework for anti-counterfeit packaging is anchored by the Drug Supply Chain Security Act of 2013, which mandated a phased transition to unit-level pharmaceutical serialization completed by November 2023. The FDA's Unique Device Identification system for medical devices, and the USDA's country-of-origin labeling requirements for food products, collectively create a multi-sector compliance architecture that structurally mandates authentication packaging across the highest-value consumer goods categories. GS1 US standards for barcoding and EPCIS data sharing are embedded into these regulatory frameworks, effectively making GS1-compliant technology a prerequisite for market participation across regulated supply chains.

On the trade policy side, the United States-Mexico-Canada Agreement (USMCA) facilitates preferential tariff treatment for authentication packaging components manufactured within the North American region, creating a trade architecture that incentivizes nearshoring of converting operations to Mexico while maintaining U.S.-based technology and software development. Import tariffs under Section 301 on Chinese-origin goods remain a persistent cost variable for converters reliant on Chinese-sourced substrates or printing equipment. The U.S. International Trade Commission has initiated anti-dumping investigations on certain specialty paper and film imports that directly affect authentication substrate supply chains, introducing additional sourcing uncertainty that procurement teams must actively manage through contract diversification and dual-sourcing strategies.

U.S. Anti-Counterfeit Packaging Supply Chain Outlook to 2032

Through 2032, the U.S. anti-counterfeit packaging supply chain will undergo a fundamental technology transition from passive optical authentication to active, connected digital authentication. RFID, NFC, and blockchain-anchored serialization will collectively displace holographic and ink-based solutions as the primary authentication mechanism across pharmaceutical, luxury, and food categories. This shift compresses margin for traditional label converters while expanding value pools for software platform providers and systems integrators. Impinj and Zebra Technologies are structurally advantaged in this transition; traditional hologram suppliers without a credible digital roadmap face revenue contraction after 2027.

Simultaneously, the reshoring of pharmaceutical and semiconductor manufacturing creates new embedded demand for authentication packaging at domestic production facilities currently under construction or in planned phases. Intel's Arizona fabrication facilities and Eli Lilly's expanded U.S. manufacturing sites represent the type of high-value production nodes where authentication must be integrated into the packaging line from day one. By 2032, the U.S. will have meaningfully reduced its import dependency for RFID inlays as domestic capacity investments respond to sustained demand signals, strengthening supply chain resilience and reducing the cost volatility that currently limits adoption in mid-market consumer goods categories.